Effects of living at moderate altitude on pulmonary vascular function and exercise capacity in mice with sickle cell anemia

Abstract

Exposure to high altitude worsens symptoms and crises in patients with sickle cell disease (SCD). However, it remains unclear if prolonged exposure to low barometric pressures exacerbates SCD etiologies or impairs quality of life. We tested the hypothesis that, relative to wild‐type (WT) mice, Berkley sickle cell mice (BERK‐SS) residing at sea level, mild (1609 m) and moderate (2438 m) altitude would have a higher rate of hemolysis, impaired cardiac function, and reduced exercise tolerance and that the level of altitude would worsen these decrements. Following 3 months of altitude exposure, right ventricular systolic pressures (RVSP) were measured (solid‐state transducer). In addition, the adaptive balance between pulmonary vascular endothelial nitric oxide synthase and endothelin was assessed in lung tissue to determine differences in pulmonary vascular adaptation and the speed/duration relationship (critical speed, CS) was used to evaluate treadmill exercise tolerance. At all altitudes, BERK‐SS mice had a significantly lower %Hct and higher total bilirubin and free hemoglobin concentration (P<0.05 for all). RVSPs in BERK‐SS were higher than WT at moderate altitude and when compared to BERK‐SS at sea level (P<0.05, for both). CS was significantly lower in BERK‐SS at mild and moderate altitude (P<0.05). BERK‐SS demonstrated exacerbated SCD complications and reduced exercise capacity associated with an increase in altitude. These results suggest that exposure to mild and moderate altitude enhances the progression of SCD in BERK‐SS mice compared to healthy WT cohorts and BERK‐SS mice at sea level and provides crucial information for the clinical counseling of SCD patients.Support or Funding InformationThis study was supported by the National Heart, Lung and Blood Institute Grants 1R01HL125642‐01A1 (Irwin DC), 1R01HL086680‐07 (Nozik‐Grayck E), 5P01HL014985‐38 (Stenmark KR), and T32‐HL007171 (Stenmark KR), Colorado Sickle Cell Treatment and Research Center (Hassell K and Nuss R).This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.